

Anna Rull

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6657974/publications.pdf>

Version: 2024-02-01

95
papers

2,904
citations

212478

28
h-index

214428

50
g-index

96
all docs

96
docs citations

96
times ranked

5370
citing authors

#	ARTICLE	IF	CITATIONS
1	Fetuinâ€A, interâ€leukin-10, trypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes. <i>Clinical and Translational Medicine</i> , 2022, 12, e704.	1.7	11
2	Adipokines as New Biomarkers of Immune Recovery: Apelin Receptor, RBP4 and ZAG Are Related to CD4+ T-Cell Reconstitution in PLHIV on Suppressive Antiretroviral Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2202.	1.8	3
3	Use of generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection in Spain. <i>AIDS Research and Human Retroviruses</i> , 2022, , .	0.5	1
4	Resistin and IL-15 as Predictors of Invasive Mechanical Ventilation in COVID-19 Pneumonia Irrespective of the Presence of Obesity and Metabolic Syndrome. <i>Journal of Personalized Medicine</i> , 2022, 12, 391.	1.1	12
5	Elevated Î±-Ketoglutaric Acid Concentrations and a Lipid-Balanced Signature Are the Key Factors in Long-Term HIV Control. <i>Frontiers in Immunology</i> , 2022, 13, 822272.	2.2	4
6	Predictive Biomarkers of COVID-19 Severity in SARS-CoV-2 Infected Patients with Obesity and Metabolic Syndrome. <i>Journal of Personalized Medicine</i> , 2021, 11, 227.	1.1	5
7	Epigenome-wide association study of COVID-19 severity with respiratory failure. <i>EBioMedicine</i> , 2021, 66, 103339.	2.7	90
8	Cardiovascular Disease in Type 1 Diabetes Mellitus: Epidemiology and Management of Cardiovascular Risk. <i>Journal of Clinical Medicine</i> , 2021, 10, 1798.	1.0	21
9	Differential miRNA plasma profiles associated with the spontaneous loss of HIVâ€1 control: miRâ€199aâ€3p and its potential role as a biomarker for quick screening of elite controllers. <i>Clinical and Translational Medicine</i> , 2021, 11, e474.	1.7	3
10	Early antiretroviral therapy initiation effect on metabolic profile in vertically HIV-1-infected children. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2993-3001.	1.3	6
11	Evolution of Serum Acute-Phase Glycoproteins Assessed by 1H-NMR in HIV Elite Controllers. <i>Frontiers in Immunology</i> , 2021, 12, 730691.	2.2	2
12	Functional impairment of HIV-specific CD8+ Tâ€cells precedes aborted spontaneous control of viremia. <i>Immunity</i> , 2021, 54, 2372-2384.e7.	6.6	20
13	Physiciansâ€TM opinions on generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection: a multicentre survey in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 466-472.	1.3	6
14	How well are we performing the initial assessment of HIVâ€positive patients? Results from a multicentre cohort in Spain. <i>HIV Medicine</i> , 2020, 21, 128-134.	1.0	0
15	Low-density lipoprotein aggregation is inhibited by apolipoprotein J-derived mimetic peptide D-[113â€122]apoJ. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2020, 1865, 158541.	1.2	7
16	Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study. <i>Lancet HIV</i> , the, 2020, 7, e565-e573.	2.1	42
17	High circulating SDF-1 and MCP-1 levels and genetic variations in CXCL12, CCL2 and CCR5: Prognostic signature of immune recovery status in treated HIV-positive patients. <i>EBioMedicine</i> , 2020, 62, 103077.	2.7	15
18	Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy. <i>Annals of Internal Medicine</i> , 2020, 173, 536-541.	2.0	280

#	ARTICLE	IF	CITATIONS
19	Increased Frequencies of Myeloid-Derived Suppressor Cells Precede Immunodiscordance in HIV-Infected Subjects. <i>Frontiers in Immunology</i> , 2020, 11, 581307.	2.2	6
20	Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study. <i>AIDS Research and Therapy</i> , 2020, 17, 45.	0.7	1
21	Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 1246.	1.0	9
22	Glycoprotein Profile Assessed by 1H-NMR as a Global Inflammation Marker in Patients with HIV Infection. A Prospective Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1344.	1.0	14
23	Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide d-[113â€“122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice. <i>Biomolecules</i> , 2020, 10, 829.	1.8	18
24	Spatiotemporal Characteristics of the Largest HIV-1 CRF02_AG Outbreak in Spain: Evidence for Onward Transmissions. <i>Frontiers in Microbiology</i> , 2019, 10, 370.	1.5	9
25	IL-7/IL-7R gene variants impact circulating IL-7/IL-7R homeostasis and ART-associated immune recovery status. <i>Scientific Reports</i> , 2019, 9, 15722.	1.6	4
26	Immunometabolism is a key factor for the persistent spontaneous elite control of HIV-1 infection. <i>EBioMedicine</i> , 2019, 42, 86-96.	2.7	55
27	Glutaminolysis and lipoproteins are key factors in late immune recovery in successfully treated HIV-infected patients. <i>Clinical Science</i> , 2019, 133, 997-1010.	1.8	21
28	Proteomic Profile Associated With Loss of Spontaneous Human Immunodeficiency Virus Type 1 Elite Control. <i>Journal of Infectious Diseases</i> , 2019, 219, 867-876.	1.9	23
29	Electronegative LDL: An Active Player in Atherogenesis or a By- Product of Atherosclerosis?. <i>Current Medicinal Chemistry</i> , 2019, 26, 1665-1679.	1.2	14
30	Circulating metabolomic profile can predict dyslipidemia in HIV patients undergoing antiretroviral therapy. <i>Atherosclerosis</i> , 2018, 273, 28-36.	0.4	15
31	A baseline metabolomic signature is associated with immunological CD4+ T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients. <i>Aids</i> , 2018, 32, 565-573.	1.0	26
32	Low-Level Viremia Is Associated With Clinical Progression in HIV-Infected Patients Receiving Antiretroviral Treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 329-337.	0.9	53
33	Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients. <i>Medicine (United States)</i> , 2018, 97, e12238.	0.4	8
34	Apolipoprotein J mimetic peptide [113â€“122]apoJ decreases weight gain in LDLR-KO mice under atherogenic diet by decreasing fat accumulation. <i>Atherosclerosis</i> , 2017, 263, e71.	0.4	1
35	Sphingomyelinase-induced ldl aggregation is blocked by apolipoprotein J mimetic peptide D-[113â€“122]apoJ. <i>Atherosclerosis</i> , 2017, 263, e204.	0.4	0
36	Thermal stability of human plasma electronegative low-density lipoprotein: A paradoxical behavior of low-density lipoprotein aggregation. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2016, 1861, 1015-1024.	1.2	6

#	ARTICLE	IF	CITATIONS
37	The role of LDL-bound apoJ in the development of atherosclerosis. <i>Clinical Lipidology</i> , 2015, 10, 321-328.	0.4	5
38	Stevia-derived compounds attenuate the toxic effects of ectopic lipid accumulation in the liver of obese mice: A transcriptomic and metabolomic study. <i>Food and Chemical Toxicology</i> , 2015, 77, 22-33.	1.8	38
39	Hypoxia worsens the impact of intracellular triglyceride accumulation promoted by electronegative low-density lipoprotein in cardiomyocytes by impairing perilipin 5 upregulation. <i>International Journal of Biochemistry and Cell Biology</i> , 2015, 65, 257-267.	1.2	12
40	Increased concentration of clusterin/apolipoprotein J (apoJ) in hyperlipemic serum is paradoxically associated with decreased apoJ content in lipoproteins. <i>Atherosclerosis</i> , 2015, 241, 463-470.	0.4	15
41	Clusterin/apolipoprotein J binds to aggregated LDL in human plasma and plays a protective role against LDL aggregation. <i>FASEB Journal</i> , 2015, 29, 1688-1700.	0.2	25
42	Understanding the role of circulating chemokine (C-C motif) ligand 2 in patients with chronic ischemia threatening the lower extremities. <i>Vascular Medicine</i> , 2014, 19, 442-451.	0.8	11
43	Polyphenols and the Modulation of Gene Expression Pathways: Can We Eat Our Way Out of the Danger of Chronic Disease?. <i>Critical Reviews in Food Science and Nutrition</i> , 2014, 54, 985-1001.	5.4	91
44	Rosiglitazone and Fenofibrate Exacerbate Liver Steatosis in a Mouse Model of Obesity and Hyperlipidemia. A Transcriptomic and Metabolomic Study. <i>Journal of Proteome Research</i> , 2014, 13, 1731-1743.	1.8	43
45	A possible role for CCR5 in the progression of atherosclerosis in HIV-infected patients: a cross-sectional study. <i>AIDS Research and Therapy</i> , 2013, 10, 11.	0.7	12
46	Multifunctional targets of dietary polyphenols in disease: A case for the chemokine network and energy metabolism. <i>Food and Chemical Toxicology</i> , 2013, 51, 267-279.	1.8	55
47	Paraoxonase-1 Deficiency Is Associated with Severe Liver Steatosis in Mice Fed a High-fat High-cholesterol Diet: A Metabolomic Approach. <i>Journal of Proteome Research</i> , 2013, 12, 1946-1955.	1.8	54
48	Exploring PPAR Modulation in Experimental Mice. <i>Methods in Molecular Biology</i> , 2013, 952, 253-273.	0.4	2
49	Paraoxonase-1 Inhibits Oxidized Low-Density Lipoprotein-Induced Metabolic Alterations and Apoptosis in Endothelial Cells: A Nondirected Metabolomic Study. <i>Mediators of Inflammation</i> , 2013, 2013, 1-9.	1.4	29
50	Mitochondrial Dysfunction: A Basic Mechanism in Inflammation-Related Non-Communicable Diseases and Therapeutic Opportunities. <i>Mediators of Inflammation</i> , 2013, 2013, 1-13.	1.4	116
51	Ubiquitous Transgenic Overexpression of C-C Chemokine Ligand 2: A Model to Assess the Combined Effect of High Energy Intake and Continuous Low-Grade Inflammation. <i>Mediators of Inflammation</i> , 2013, 2013, 1-19.	1.4	13
52	Metformin: a cheap and well-tolerated drug that provides benefits for viral infections. <i>HIV Medicine</i> , 2013, 14, 233-240.	1.0	16
53	Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil. <i>Cell Cycle</i> , 2013, 12, 555-578.	1.3	131
54	The Deleterious Influence of Tenofovir-Based Therapies on the Progression of Atherosclerosis in HIV-Infected Patients. <i>Mediators of Inflammation</i> , 2012, 2012, 1-9.	1.4	5

#	ARTICLE	IF	CITATIONS
55	Serum paraoxonase-3 concentration in HIV-infected patients. Evidence for a protective role against oxidation. <i>Journal of Lipid Research</i> , 2012, 53, 168-174.	2.0	15
56	PPARs in Regulation of Paraoxonases: Control of Oxidative Stress and Inflammation Pathways. <i>PPAR Research</i> , 2012, 2012, 1-10.	1.1	43
57	Monocyte chemoattractant protein-1 and paraoxonase-1 and 3 levels in patients with sepsis treated in an intensive care unit: a preliminary report. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 1409-15.	1.4	20
58	Serum paraoxonase-3 concentration is associated with insulin sensitivity in peripheral artery disease and with inflammation in coronary artery disease. <i>Atherosclerosis</i> , 2012, 220, 545-551.	0.4	24
59	Plant-derived polyphenols regulate expression of miRNA paralogs miR-103/107 and miR-122 and prevent diet-induced fatty liver disease in hyperlipidemic mice. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2012, 1820, 894-899.	1.1	117
60	The Level of DING Proteins Is Increased in HIV-Infected Patients: In Vitro and In Vivo Studies. <i>PLoS ONE</i> , 2012, 7, e33062.	1.1	7
61	Human Duffy blood group alloantigen system influences the measurement of monocyte chemoattractant protein-1 (MCP-1) in serum but not in plasma. <i>Clinical Laboratory</i> , 2012, 58, 185-8.	0.2	7
62	Serum fatty acid synthase concentration is increased in patients with hepatitis viral infection and may assist in the prediction of liver steatosis. <i>Journal of Clinical Virology</i> , 2011, 51, 199-201.	1.6	19
63	Serum paraoxonase-3 concentration is associated with the severity of hepatic impairment in patients with chronic liver disease. <i>Clinical Biochemistry</i> , 2011, 44, 1320-1324.	0.8	16
64	Immunohistochemical analysis of paraoxonases-1 and 3 in human atheromatous plaques. <i>European Journal of Clinical Investigation</i> , 2011, 41, 308-314.	1.7	48
65	Continuous administration of polyphenols from aqueous rooibos (<i>Aspalathus linearis</i>) extract ameliorates dietary-induced metabolic disturbances in hyperlipidemic mice. <i>Phytomedicine</i> , 2011, 18, 414-424.	2.3	79
66	Antiretroviral treatment-induced dyslipidemia in HIV-infected patients is influenced by the APOC3-related rs10892151 polymorphism. <i>BMC Medical Genetics</i> , 2011, 12, 120.	2.1	9
67	Measurement of serum PON-3 concentration: method evaluation, reference values, and influence of genotypes in a population-based study. <i>Journal of Lipid Research</i> , 2011, 52, 1055-1061.	2.0	21
68	The Role of Combined Assessment of Defense Against Oxidative Stress and Inflammation in the Evaluation of Peripheral Arterial Disease. <i>Current Molecular Medicine</i> , 2011, 11, 453-464.	0.6	18
69	Differential response of two models of genetically modified mice fed with high fat and cholesterol diets: relationship to the study of non-alcoholic steatohepatitis. <i>Molecular and Cellular Biochemistry</i> , 2010, 343, 59-66.	1.4	13
70	Tissue distribution and expression of paraoxonases and chemokines in mouse: the ubiquitous and joint localisation suggest a systemic and coordinated role. <i>Journal of Molecular Histology</i> , 2010, 41, 379-386.	1.0	46
71	The aqueous extract of <i>Hibiscus sabdariffa</i> calices modulates the production of monocyte chemoattractant protein-1 in humans. <i>Phytomedicine</i> , 2010, 17, 186-191.	2.3	85
72	Infection with HIV and HCV enhances the release of fatty acid synthase into circulation: evidence for a novel indicator of viral infection. <i>BMC Gastroenterology</i> , 2010, 10, 92.	0.8	18

#	ARTICLE	IF	CITATIONS
73	Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation. <i>HIV Medicine</i> , 2010, 11, 225-231.	1.0	89
74	Pitfalls in measuring high-density lipoprotein cholesterol concentrations in HIV-infected patients. <i>HIV Medicine</i> , 2010, 11, 260-265.	1.0	0
75	Human immunodeficiency virus-infection induces major changes in high-density lipoprotein particle size distribution and composition: the effect of antiretroviral treatment and disease severity. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 1147-52.	1.4	12
76	Insulin Resistance, Inflammation, and Obesity: Role of Monocyte Chemoattractant Protein-1 (orCCL2) in the Regulation of Metabolism. <i>Mediators of Inflammation</i> , 2010, 2010, 1-11.	1.4	108
77	Expression of cytokine genes in the aorta is altered by the deficiency in MCP-1: Effect of a high-fat, high-cholesterol diet. <i>Cytokine</i> , 2010, 50, 121-128.	1.4	20
78	Host-pathogen interactions in the development of metabolic disturbances and atherosclerosis in HIV infection: The role of CCL2 genetic variants. <i>Cytokine</i> , 2010, 51, 251-258.	1.4	11
79	Metabolomic Assessment of the Effect of Dietary Cholesterol in the Progressive Development of Fatty Liver Disease. <i>Journal of Proteome Research</i> , 2010, 9, 2527-2538.	1.8	141
80	Decreased paraoxonase-1 activity is associated with alterations of high-density lipoprotein particles in chronic liver impairment. <i>Lipids in Health and Disease</i> , 2010, 9, 46.	1.2	32
81	Methodological constraints in interpreting serum paraoxonase-1 activity measurements: an example from a study in HIV-infected patients. <i>Lipids in Health and Disease</i> , 2010, 9, 32.	1.2	11
82	Interrelationships Between Paraoxonase-1 and Monocyte Chemoattractant Protein-1 in the Regulation of Hepatic Inflammation. <i>Advances in Experimental Medicine and Biology</i> , 2010, 660, 5-18.	0.8	17
83	Serum concentrations of extracellular fatty acid synthase in patients with steatohepatitis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 1097-9.	1.4	7
84	Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease. <i>BMC Gastroenterology</i> , 2009, 9, 3.	0.8	83
85	Treatment of hypertriglyceridemia and HIV: fenofibrate-induced changes in the expression of chemokine genes in circulating leukocytes. <i>AIDS Research and Therapy</i> , 2009, 6, 26.	0.7	3
86	Hepatic monocyte chemoattractant protein-1 is upregulated by dietary cholesterol and contributes to liver steatosis. <i>Cytokine</i> , 2009, 48, 273-279.	1.4	48
87	Metabolic phenotyping of genetically modified mice: An NMR metabonomic approach. <i>Biochimie</i> , 2009, 91, 1053-1057.	1.3	23
88	Changes in the expression of genes related to apoptosis and fibrosis pathways in CCl4-treated rats. <i>Molecular and Cellular Biochemistry</i> , 2008, 308, 101-109.	1.4	10
89	Moderately High Folic Acid Supplementation Exacerbates Experimentally Induced Liver Fibrosis in Rats. <i>Experimental Biology and Medicine</i> , 2008, 233, 38-47.	1.1	14
90	The results in rodent models of atherosclerosis are not interchangeable. <i>Atherosclerosis</i> , 2007, 195, e85-e92.	0.4	55

#	ARTICLE	IF	CITATIONS
91	Deficiency in monocyte chemoattractant protein-1 modifies lipid and glucose metabolism. <i>Experimental and Molecular Pathology</i> , 2007, 83, 361-366.	0.9	26
92	Experimentos con ratones susceptibles a arteriosclerosis. Ventajas, inconvenientes y aspectos que considerar. <i>Clinica E Investigaci3n En Arteriosclerosis</i> , 2006, 18, 155-163.	0.4	1
93	Dietary cholesterol and differential monocyte chemoattractant protein-1 gene expression in aorta and liver of apo E-deficient mice. <i>Biochemical and Biophysical Research Communications</i> , 2006, 340, 1078-1084.	1.0	53
94	Manipulation of inflammation modulates hyperlipidemia in apolipoprotein E-deficient mice: A possible role for interleukin-6. <i>Cytokine</i> , 2006, 34, 224-232.	1.4	16
95	Genetic association of paraoxonase-1 polymorphisms and chronic hepatitis C virus infection. <i>Clinica Chimica Acta</i> , 2005, 361, 206-210.	0.5	35